In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharma in 2008: What a Difference an Economic Crisis Makes

Executive Summary

Even before the financial meltdown, 2008 was a remodeling year for the biopharmaceutical world. Many pharma companies, more reliant on the product candidates and technologies of the biotech world than ever, were pinned down by excess infrastructure and lagging productivity. But when the world's cash dried up, so, too, did biotech's leverage over those downtrodden in-licensers and acquirers. We highlight some top trends from a difficult year that may shape industry in 2009 and beyond.

Related Content

Biopharma Trends: Nowhere To Go But Up
2008's Top Biopharma Dealmakers
Merck's Head-long Leap into Follow-On Biologics
Economic Forecast for Pharma: Winter Weather Advisory Ahead
Pfizer's Increasingly Specialist Focus
Can Big Pharma Save Biotech Investors?
Pharma's Strategic Divide: Focus or Diversify
Alzheimer's Development Financing: Risky Therapies Call for Innovative Deals
Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way
Novartis' New Kind of Pharma Deal


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts